The emergence of drugs like copyright and Semaglutide signifies a major shift in how we approach metabolic disorders. These groundbreaking therapies belong to a class known as GLP-1 action agonists, which mimic the effects of a natural hormone that controls blood sugar levels and hunger. First, developed for diabetic conditions, their effectiveness